Clinical Experience of Use of Sacubitril/Valsartan in a Patient with Dilated Cardiomyopathy, Chronic Heart Failure with Reduced Ejection Fraction and Ventricular Arrhythmias

Abstract

Chronic heart failure is the final stage of the cardiovascular continuum, which is an important cause of disability and reduced life expectancy in developed countries. Optimal medical therapy recommended for patients with symptomatic HF and reduced left ventricular ejection fraction includes angiotensin-converting enzyme inhibitors (or angiotensin II receptor antagonists), beta-blockers and mineralocorticoid receptor antagonists. However, the use of optimal medical therapy does not always lead to the elimination of symptoms, improvement of the quality of life and functional capabilities of patients.

Sakubitril/valsartan is a novel combination drug that includes the angiotensin II receptor blocker valsartan and the neprilisin inhibitor sacubitril. In a large PARADIGM-HF clinical trial it demonstrated a 20% reduction in cardiovascular mortality and hospitalization due to decompensation of heart failure compared with standard therapy with enalapril. We report a case of successful use of sacubitril/valsartan in a 61-year-old patient with dilated cardiomyopathy, chronic heart failure with reduced ejection fraction and ventricular arrhythmias. After 6 months of therapy, the patient achieved marked positive dynamics of the clinical status, laboratory and instrumental parameters in absence of any adverse reactions and complications.

Keywords

sacubitril/valsartan / heart failure with reduced ejection fraction / dilated cardiomyopathy / ventricular arrhythmias / case report

References

[1] McKenna WJ, Maron BJ, Thiene G. Classification, epidemiology, and global burden of cardiomyopathies. Circ Res. 2017;121(7): 722–730. DOI: 10.1161/CIRCRESAHA.117.309711

[2] McKenna W.J., Maron B.J., Thiene G. Classification, Epidemiology, and Global Burden of Cardiomyopathies // Circ. Res. 2017. Vol. 121, No. 7. P. 722–730. DOI: 10.1161/CIRCRESAHA.117.309711

[3] Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5(1):32. DOI: 10.1038/s41572-019-0084-1

[4] Schultheiss H.P., Fairweather D., Caforio A.L.P. et al. Dilated cardiomyopathy // Nat. Rev. Dis. Primers. 2019. Vol. 5, No. 1. P. 1–32. DOI: 10.1038/s41572-019-0084-1

[5] Braunwald E. Cardiomyopathies: an overview. Circ Res. 2017;121(7):711–721. DOI: 10.1161/CIRCRESAHA.117.311812

[6] Braunwald E. Cardiomyopathies: an overview // Circ. Res. 2017. Vol. 121, No. 7. P. 711–721. DOI: 10.1161/CIRCRESAHA.117.311812

[7] Bakalakos A, Ritsatos K, Anastasakis A. Current perspectives on the diagnosis and management of dilated cardiomyopathy Beyond heart failure: a Cardiomyopathy Clinic Doctor’s point of view. Hellenic J Cardiol. 2018;59(5):254–261. DOI: 10.1016/j.hjc.2018.05.008

[8] Bakalakos A., Ritsatos K., Anastasakis A. Current perspectives on the diagnosis and management of dilated cardiomyopathy beyond heart failure: a Cardiomyopathy Clinic Doctor’s point of view // Hellenic J. Cardiol. 2018. Vol. 59, No. 5. P. 254–261. DOI: 10.1016/j.hjc.2018.05.008

[9] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. DOI: 10.1002/ejhf.592

[10] Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. J. Heart Fail. 2016. Vol. 18, No. 8. P. 891–975. DOI: 10.1002/ejhf.592

[11] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC / AHA / HFSA Focused Update of the 2013 ACCF / AHAGuideline for the Management of Heart Failure: A Report of theAmerican College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–161. DOI: 10.1161/CIR.0000000000000509

[12] Yancy C.W., Jessup M., Bozkurt B. et al. 2017 ACC / AHA / HFSA Focused Update of the 2013 ACCF / AHAGuideline for the Management of Heart Failure: A Report of theAmerican College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America // Circulation. 2017. Vol. 136, No. 6. P. 137–161. DOI: 10.1161 / CIR.0000000000000509

[13] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. DOI: 10.1056/NEJMoa1409077

[14] McMurray J.J., Packer M., Desai A.S. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure // N. Engl. J. Med. 2014. Vol. 371, No. 11. P. 993–1004. DOI: 10.1056/NEJMoa1409077

[15] Kaur N, Pruthvi CR, Rohit M. Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction? Egypt Heart J. 2021;73(1):26. DOI: 10.1186/s43044-021-00152-x

[16] Kaur N., Pruthvi C.R., Rohit M. Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction? // Egypt. Heart J. 2021. Vol. 73, No. 1. P. 1–26. DOI: 10.1186/s43044-021-00152-x

[17] Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021;11(1):263–276. DOI: 10.21037/cdt-20-302

[18] Schwinger R.H.G. Pathophysiology of heart failure // Cardiovasc. Diagn. Ther. 2021. Vol. 11, No. 1. P. 263–276. DOI: 10.21037/cdt-20-302

[19] Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 years after PARADIGM-HF. JACC Heart Fail. 2020;8(10):800–810. DOI: 10.1016/j.jchf.2020.06.020

[20] Docherty K.F., Vaduganathan M., Solomon S.D., McMurray J.J.V. Sacubitril/Valsartan: Neprilysin Inhibition 5 years after PARADIGM-HF // JACC Heart Fail. 2020. Vol. 8, No. 10. P. 800–810. DOI: 10.1016/j.jchf.2020.06.020

[21] D’Alessandra Y, Chiesa M, Carena MC, et al. Differential role of circulating microRNAs to track progression and pre-symptomatic stage of chronic heart failure: a pilot study. Biomedicines. 2020;8(12):597. DOI: 10.3390/biomedicines8120597

[22] D’Alessandra Y., Chiesa M., Carena M.C. et al. Differential role of circulating microRNAs to track progression and pre-symptomatic stage of chronic heart failure: a pilot study // Biomedicines. 2020. Vol. 8, No. 12. P. 597. DOI: 10.3390/biomedicines8120597

[23] Corrado E, Saladino A, Morgante G, et al. Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report. Clin Case Rep. 2020;8(8):1349–1352. DOI: 10.1002/ccr3.2655

[24] Corrado E., Saladino A., Morgante G. et al. Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report // Clin. Case Rep. 2020. Vol. 8, No. 8. P. 1349–1352. DOI: 10.1002/ccr3.2655

[25] Cameli M, Pastore MC, Pagliaro A, et al. Sacubitril/Valsartan in an elderly patient with heart failure: a case report. Cardiology. 2017;138(suppl 1):3–6. DOI: 10.1159/000484867

[26] Cameli M., Pastore M.C., Pagliaro A. et al. Sacubitril/Valsartan in an elderly patient with heart failure: a case report // Cardiology. 2017. Vol. 138 Suppl 1. P. 3–6. DOI: 10.1159/000484867

[27] Hu J, Wu Y, Zhou X, et al. Beneficial effects of Sacubitril/Valsartan at low doses in an Asian real-world heart failure population. J Cardiovasc Pharmacol. 2020;76(4):445–451. DOI: 10.1097/FJC.0000000000000873

[28] Hu J., Wu Y., Zhou X. et al. Beneficial Effects of Sacubitril/Valsartan at low doses in an Asian real-world heart failure population // J. Cardiovasc. Pharmacol. 2020. Vol. 76, No. 4. P. 445–451. DOI: 10.1097/FJC.0000000000000873

[29] Sauer AJ, Cole R, Jensen BC, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019;24(2):167–176. DOI: 10.1007/s10741-018-9757-1

[30] Sauer A.J., Cole R., Jensen B.C. et al. Practical guidance on the use of sacubitril/valsartan for heart failure // Heart Fail. Rev. 2019. Vol. 24, No. 2. P. 167–176. DOI: 10.1007/s10741-018-9757-1

[31] Golukhova EZ, Gromova O, Grigoryan M, et al. Noninvasive predictors of malignant arrhythmias. Cardiology. 2016;135:36–42. DOI: 10.1159/000445881

[32] Golukhova E.Z., Gromova O., Grigoryan M. et al. Noninvasive predictors of malignant arrhythmias // Cardiology. 2016. Vol. 135, No. 1. P. 36–42. DOI: 10.1159/000445881

[33] Balla C, Vitali F, Brieda A, et al. Predictors of cardiac arrhythmic events in non coronary artery disease patients. BMC Cardiovasc Disord. 2019;19(1):104. DOI: 10.1186/s12872-019-1083-6

[34] Balla C., Vitali F., Brieda A. et al. Predictors of cardiac arrhythmic events in non coronary artery disease patients // BMC Cardiovasc. Disord. 2019. Vol. 19, No. 1. P. 104. DOI: 10.1186/s12872-019-1083-6

[35] Lepojarvi ES, Huikuri HV, Piira OP, et al. Biomarkers as predictors of sudden cardiac death in coronary artery disease patients with preserved left ventricular function (ARTEMIS study). PLoS ONE. 2018;13(9):e0203363. DOI: 10.1371/journal.pone.0203363

[36] Lepojarvi E.S., Huikuri H.V., Piira O.P. et al. Biomarkers as predictors of sudden cardiac death in coronary artery disease patients with preserved left ventricular function (ARTEMIS study) // PLoS ONE. 2018. Vol. 13, No. 9. P. e0203363. DOI: 10.1371/journal.pone.0203363

[37] De Diego C, González-Torres L, Núñez JM, et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 2018;15(3):395–402. DOI: 10.1016/j.hrthm.2017.11.012

[38] Diego C., González-Torres L., Núñez J.M. et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices // Heart Rhythm. 2018. Vol. 15, No. 3. P. 395–402. DOI: 10.1016/j.hrthm.2017.11.012

[39] Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61–73. DOI: 10.1016/S0140-6736(18)32484-X

[40] Halliday B.P., Wassall R., Lota A.S. et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial // Lancet. 2019. Vol. 393, No. 10166. P. 61–73. DOI: 10.1016/S0140-6736(18)32484-X

[41] Grant ADM, Chew DS, Howlett JG, Miller RJH. Cost-effectiveness of earlier transition to angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction. CJC Open. 2020;2(6):447–453. DOI: 10.1016/j.cjco.2020.05.009

[42] Grant A.D.M., Chew D.S., Howlett J.G., Miller R.J.H. Cost-effectiveness of earlier transition to angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction // CJC Open. 2020. Vol. 2, No. 6. P. 447–453. DOI: 10.1016/j.cjco.2020.05.009

RIGHTS & PERMISSIONS

Snezhitskiy V.A., Kalatsei L.V., Matyukevich M.C., Grib S.N., Snezhickaya E.А., Madekina G.А., Epifanova Z.G., Chernaya E.N.